Skip to content

Feed Screener Search Methodology

SEC · FI · BAFIN · AFM · AMF

Pricing Sign in

InsiderLens

Statistics predict. AI explains.

Insider transactions from public regulatory disclosures, aggregated and enriched with deterministic statistical signals. Not investment advice.

Sources

SEC EDGAR · US
FINANSINSPEKTIONEN · SE
BAFIN · DE
AFM · NL
AMF · FR

Product

Methodology
Privacy notice
Object to processing

Feed Screener Search Methodology

Pricing Sign in

Suh Carol Y. — Neumora Therapeutics, Inc. insider: 2 transactions · InsiderLens

Home / Insiders / Suh Carol Y.

Suh Carol Y.

Chief Operating Officer at Neumora Therapeutics, Inc. · on record since Sep 14, 2023

Insider trading activity of Suh Carol Y.

Transactions on record: 2; since Feb 16, 2024

Open-market buys: 0

Open-market sells: 0

Companies traded: 1; last filing Feb 16, 2024

Figures computed from official regulatory filings — methodology.

Companies where Suh Carol Y. has traded

Neumora Therapeutics, Inc.2 tx · Feb 16, 2024

Track record of Suh Carol Y.

Insufficient history for a statistical track record (fewer than 5 open-market buys).

Transaction history of Suh Carol Y.

Co-insiders of Suh Carol Y.

AMGEN INCNeumora Therapeutics, Inc.
ARCH Venture Fund VIII Overage, L.P.Neumora Therapeutics, Inc.
Arch Venture Fund VII LPNeumora Therapeutics, Inc.
ARCH Venture Fund XII, L.P.Neumora Therapeutics, Inc.
ARCH Venture Fund X, L.P.Neumora Therapeutics, Inc.
ARCH Venture Fund X Overage, L.P.Neumora Therapeutics, Inc.
ARCH Venture Partners VIII, LLCNeumora Therapeutics, Inc.

This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →

ARCH Venture Partners VII, LLCNeumora Therapeutics, Inc.

ARCH Venture Partners VII, L.P.Neumora Therapeutics, Inc.

ARCH Venture Partners XII, LLCNeumora Therapeutics, Inc.

ARCH Venture Partners XII, L.P.Neumora Therapeutics, Inc.

ARCH Venture Partners X, LLCNeumora Therapeutics, Inc.

ARCH Venture Partners X, L.P.Neumora Therapeutics, Inc.

ARCH Venture Partners X Overage, L.P.Neumora Therapeutics, Inc.

Aurora Daljit SinghNeumora Therapeutics, Inc.

BERNS PAUL LNeumora Therapeutics, Inc.

Burow KristinaNeumora Therapeutics, Inc.

BYBEE CLINTONNeumora Therapeutics, Inc.

CRANDELL KEITHNeumora Therapeutics, Inc.

Duncan JasonNeumora Therapeutics, Inc.

FMR LLCNeumora Therapeutics, Inc.

Fust Matthew KNeumora Therapeutics, Inc.

GILLIS STEVENNeumora Therapeutics, Inc.

Gosebruch Henry ONeumora Therapeutics, Inc.

Halawa AlaaNeumora Therapeutics, Inc.

Ho MaykinNeumora Therapeutics, Inc.

Lenz Robert A.Neumora Therapeutics, Inc.

Milligan Michael LeeNeumora Therapeutics, Inc.

NELSEN ROBERTNeumora Therapeutics, Inc.

Piacquad DavidNeumora Therapeutics, Inc.

Pinto JoshuaNeumora Therapeutics, Inc.

Company	Filed	Type	Qty	Price	Value · USD	Src
Neumora Therapeutics, Inc.	Feb 16, 2024	Award	85,000	0.00 USD	$0	SEC
Neumora Therapeutics, Inc.	Feb 16, 2024	AwardD	170,000	0.00 USD	$0	SEC